DTIL earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -2.00. Updated 2026-07-23.
Precision BioSciences (DTIL) Research Hub
Precision BioSciences (DTIL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 7.17 USD (-1.10%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.00, market cap 0.09B. This hub links to the full technical, earnings and options research available for DTIL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.17 USD (-1.10%) |
| 52-week range | 6.1 USD – 9.62 USD |
| Trend regime | Range |
| 14-day RSI | 45.6 (Neutral) |
| Trailing P/E | -2.00 |
| Market cap | 0.09B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for DTIL
Covered Call on DTIL: how it works, illustrative setup around the real 7.17 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DTIL: how it works, illustrative setup around the real 7.17 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DTIL: how it works, illustrative setup around the real 7.17 USD price, max profit/loss, breakeven and when to use it. Educational.
DTIL technical analysis: range, last 7.17 USD, RSI 45.6, 52w range 6.1 USD–9.62 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is DTIL in?
Precision BioSciences (DTIL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is DTIL in an uptrend or downtrend?
As of 2026-09-11, DTIL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DTIL's trailing P/E ratio?
DTIL's trailing P/E is -2.00, with a market cap of 0.09B. See the earnings research page for full valuation detail.
When does DTIL next report earnings?
DTIL is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.71 USD.